MSF Field Research > 1 Published Research and Commentary > TB > Rational use of moxifloxacin for tuberculosis treatment

Please use this identifier to cite or link to this item:     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!

Download this article:
View/Open File Description Size Format
110401_Cox_Rational-Use-of-Moxifloxacin_Lancet-Infect-Dis-11-4-259-60.pdfMain Article40KbAdobe PDF

Title: Rational use of moxifloxacin for tuberculosis treatment
Authors: Cox, Helen
Ford, Nathan
Keshavjee, Salmaan
McDermid, Cheryl
von Schoen-Angerer, Tido
Mitnick, Carole
Goemaere, Eric
Affiliation: Burnet Institute, Melbourne, Australia; Médecins Sans Frontières, Johannesburg, South Africa; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa; Harvard Medical School, Boston, USA; Partners in Health, Boston, USA; Médecins Sans Frontières Campaign for Access to Essential Medicines, Geneva, Switzerland
Citation: Lancet Infect Dis 2011;11(4):259-60
Journal: The Lancet Infectious Diseases
Issue Date: 1-Apr-2011
DOI: 10.1016/S1473-3099(11)70036-6
PubMed ID: 21453864
Additional Links:
Type: Article
Language: en
MeSH: Tuberculosis
Tuberculosis, Multidrug-Resistant
ISSN: 1474-4457
Rights: Published by Elsevier Reproduced on this site with permission of Elsevier Ltd. Please see for further relevant comment.
Appears in topics: TB

Related articles on PubMed
Moxifloxacin for tuberculosis.
Singh KP, Brown M, Murphy ME, Gillespie SH
2012 Mar
Moxifloxacin for tuberculosis.
Mendel C, Springsklee M
2012 Mar
See all 100 articles

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.


OR Logo Powered by Open Repository | Cookies


MSF logo MSF Field Research

Sep 4, 2015